A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression
The goal of this trial is to demonstrate the potential clinical benefit of targeted
irinotecan chemotherapy in NSCLC patients whose tumors display a specific phenotype that is
associated with increased sensitivity to this drug, ISG15H.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Change in tumor size will be measured by CT scan using RECIST criteria.
Monte Shaheen, MD
UNM Cancer Center
United States: Food and Drug Administration
|University of New Mexico Cancer Center||Albuquerque, New Mexico 87131-5636|
|New Mexico Cancer Care Associates||Santa Fe, New Mexico 87505-7670|
|Hematology Oncology Associates||Albuquerque, New Mexico 87106|